Skip to main content

PD-1 and PD-L1 Inhibitor Market Future Business Opportunities 2023-2028 | Pfizer Inc., Novartis AG, AstraZeneca PLC

 


The global PD-1 and PD-L1 inhibitor market was valued at US$ 30,535.5 Mn in 2021 and is forecast to reach a value of US$ 77,541.1 Mn by 2028 at a CAGR of 14.2% between 2022 and 2028. The global PD-1 and PD-L1 inhibitor market is experiencing strong growth due to the rise in incidence or prevalence of cancer and growing geriatric population around the world. Moreover, increase in awareness among people about immune checkpoint inhibitors is expected to boost the growth of the market. However, high cost of cancer treatment and risk of complications associated with the treatment is expected to hamper growth of the global PD-1 and PD-L1 inhibitor market.

Global PD-1 and PD-L1 Inhibitor Market: Regional Insights

Based on geography, the PD-1 and PD-L1 inhibitor market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market during the forecast period owing to the increasing prevalence of cancer and favourable initiatives by the regulatory authorities in the region, especially in the United States. For instance, PD-1 and PD-L1 inhibitors are vital immune checkpoint inhibitors used to treat variety of cancer. According to the American Cancer Society, in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. This in turn is expected to increase demand for PD-1 and PD-L1 inhibitors in the region.

Asia Pacific is also expected to witness significant growth in the global PD-1 and PD-L1 inhibitor market owing to the high prevalence of cancer together with growing geriatric population in this region, especially in India. For instance, according to the cancer report by the Indian Council of Medical Research (ICMR), India’s cancer cases could increase by 12% in the next five years, with 1.5 million people projected to suffer from the non-communicable disease by 2025, up from 1.39 million in 2020. This in turn is expected to increase demand for PD-1 and PD-L1 inhibitors.

Global PD-1 and PD-L1 Inhibitor Market Restraints:

High cost of cancer treatment is expected to hamper growth of the global PD-1 and PD-L1 inhibitor market. For instance, on average, the cost of cancer treatment in India is around INR 503,118 (US$ 6,300) with a minimum expense of INR 90,561 (US$ 1,134) and maximum cost of INR 27,67,149 (USD 34,650). Moreover, the cost of available PD-1 and PD-L1 inhibitors is high, however, the cost of cancer treatment depends on the stage of the cancer.

 

Comments

Popular posts from this blog

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

  A primary driver for this market is the worldwide increase in occurrence of diabetes and cancer, across all age groups. According to the World Health Organization (WHO) 2018 statistics, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Moreover according to the World Health Organization cancer factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.  Furthermore, increasing old age population is another driver, which is anticipated to create a high growth scenario for the market. As per the World Population Prospects 2019 revision, the number of people aged 80 years or over is projected to be triple, from 143 million in 2019 to 426 million in 2050. Alternatively, factors restraining the market are complications and risks associated with the treatment including diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications....

North America is expected to lead the global cosmetology market due to growing number of minimally invasive surgeries in the region

  Market Overview: Cosmetology is the field of a beauty practice that includes a variety of practices aimed at making individual’s look and feel their best. Competitive Landscape: GC Aesthetics, Mentor Worldwide LLC, Sientra Inc., Zimmer Holdings Inc., 3M Health Care, Allergan, Inc., Implantech Associates Inc., Institut Straumann AG, Nobel Biocare Holding AG, and Spectrum Designs Medical.   Key Market Drivers: An increasing number of cosmetic surgeries is expected to expand the global cosmetology market size. For instance, according to American Society of Plastic Surgeons (ASPS) 2017 reports, around 17.5 million cosmetic surgeries were performed in 2017, U.S. among which breast augmentation, liposuction, and nose reshaping were the top three procedures. High preferences for Botox surgeries which are used to reduce wrinkles and maintain youthful skin is again fostering the growth of the market growth. According to the same source, around 65% of women prefer Botul...

Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market is Expected to Grow Drastically, Assured By Experts From 2023 To 2028

  Surgical hemostat is a surgical tool used in many surgical procedures to control bleeding. Surgical hemostats covered in this report include thrombin-based, combination hemostats, oxidized regenerated cellulose-based, gelatin-based, and collagen-based. Internal tissue sealants are typically used in surgeries to bind or hold internal tissues such as blood vessels, internal organs, bone cartilage, dura matter and others. The global surgical hemostats, internal tissue sealants and adhesion barriers market is estimated to account for US$ 4,231.4 Mn in terms of value in 2020 and is expected to reach US$ 7,346.7 Mn by the end of 2027 Global Surgical Hemostats, Internal Tissue Sealants and Adhesion Barriers Market: Drivers Increasing number of surgical procedures is expected to propel growth of the global surgical  hemostats , internal tissue sealants and adhesion barriers market over the forecast period. For instance, according to ‘Surgical operations and procedures sta...